Risevistinel is under clinical development by Aptinyx and currently in Phase I for Opium (Opioid) Addiction. According to GlobalData, Phase I drugs for Opium (Opioid) Addiction have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Risevistinel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Risevistinel overview
Risevistinel (NYX-783) is under development for the treatment of opioid use disorder and alcohol use disorder. It is administered by oral route using a once-per-day capsule formulation. It acts by targeting N-methyl D-aspartate (NMDAR) receptors.
It was also under development for the treatment of post-traumatic stress disorder.
Aptinyx overview
Aptinyx Inc (Aptinyx) is a pharmaceutical and healthcare company. It is headquartered in Foxborough, Massachusetts, the US.
For a complete picture of Risevistinel’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.